meta|Evidence - COVID-19
click on circles to display study description...
thalidomide (n=30) vs. standard of care (n=30)
randomized controlled trial high risk of bias
Thalidomide
Thalidomide tablets 100 mg daily for 14 days added to the usual treatment
Usual care
Patients in both groups received methylprednisolone 50 mg intravenously every 12 hours for 3 days andthen daily for 7 days, hydroxychloroquine 200 mg orally every 12 hours for 5 days. Antibiotics were administered based on physician choice (Ceftriaxone, Azithromycin, and Vancomycin). All patients received enoxaparin 40 mg subcutaneously daily during hospitalization.
COVID-19 severe or critically
1- 18-75 year old men and 50-75 year old women admitted in hospital 2-Spo2 less than 85% in admission 3-Clinical symptoms and signs compatible with COVID19 infection and positive PCR test or lung HRCT abnormalities compatible with COVID19 pneumonia 4-No need to intubation in first 24 hour of admission 5-No multiorgan failure at presentation 6- No shock state at presentation 7- Obtained informed consent Exclusion criteria: 1. Hepatic failure (Child Pugh score ≥ C, AST> 5 times of the upper limit normal) 2. Severe renal dysfunction (GFR less than 30cc per min)
Open-label.
Single center, Khorshid hopsital, Isfahan, Iran.
All patients were visited daily by an Internist or Pulmonologist and were followed weekly for 4 weeks using phone calls.
powered by vis.js Network